Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study

被引：33

作者：

Kita, Mariko ^{[1
]}

Fox, Robert J. ^{[2
]}

Phillips, J. Theodore ^{[3
]}

Hutchinson, Michael ^{[4
]}

Havrdova, Eva ^{[5
]}

Sarda, Sujata P. ^{[6
]}

Agarwal, Sonalee ^{[6
]}

Kong, Jessica ^{[6
]}

Zhang, Annie ^{[6
]}

Viglietta, Vissia ^{[6
]}

Sheikh, Sarah I. ^{[6
]}

Seidman, Emily ^{[7
]}

Dawson, Katherine T. ^{[6
]}

机构：

[1] Virginia Mason Med Ctr, Neurosci Inst, Seattle, WA 98101 USA

[2] Cleveland Clin, Mellen Ctr Multiple Sclerosis Treatment & Res, Dept Neurol, Cleveland, OH 44106 USA

[3] Baylor Inst Immunol Res, Multiple Sclerosis Program, Dallas, TX USA

[4] St Vincents Univ Hosp, Dept Neurol, Dublin 4, Ireland

[5] Charles Univ Prague, Fac Med 1, Dept Neurol, Prague, Czech Republic

[6] Biogen Idec Inc, Cambridge, MA USA

[7] CircleSci, Tytherington, England

来源：

MULTIPLE SCLEROSIS JOURNAL | 2014年 / 20卷 / 02期

关键词：

Multiple sclerosis; relapsing-remitting; BG-12; dimethyl fumarate; quality of life; glatiramer acetate; randomized controlled trial; PLACEBO-CONTROLLED PHASE-3; ORAL BG-12;

D O I：

10.1177/1352458513507818

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Multiple sclerosis (MS) has a significant impact on health-related quality of life (HRQoL) with symptoms adversely affecting many aspects of everyday living. BG-12 (dimethyl fumarate) demonstrated significant efficacy in the phase III studies DEFINE and CONFIRM in patients with relapsing-remitting MS. In CONFIRM, HRQoL was worse in patients with greater disability at baseline, and who relapsed during the study, and improved with BG-12 treatment. Mean Short Form-36 Physical Component Summary scores for BG-12 increased over 2 years and scores for placebo decreased. Coupled with clinical and neuroradiological benefits, these HRQoL results further support BG-12 as an effective oral treatment for relapsing MS.

引用

页码：253 / 257

页数：5

共 50 条

[21] Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis
Putzki, N.
Fischer, J.
Gottwald, K.
Reifschneider, G.
Ries, S.
Siever, A.
Hoffmann, F.
Kaefferlein, W.
Kausch, U.
Liedtke, M.
Kirchmeier, J.
Gmuend, S.
Richter, A.
Schicklmaier, P.
Niemczyk, G.
Wernsdoerfer, C.
Hartung, H. P.
EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 (06) : 713 - 720
[22] Tremor in Patients with Relapsing-Remitting Multiple Sclerosis: Clinical Characteristics and Impact on Quality of Life
Shalash, Ali
Elhodeby, Ahmed Mohamed
Saad, Mahmoud
Ibrahim, Yosra Abdelzaher
Hamid, Eman
Nasef, Ayman
MOVEMENT DISORDERS CLINICAL PRACTICE, 2023, 10 (07): : 1099 - 1106
[23] Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study
Comi, Giancarlo
Leocani, Letizia
Ferini-Strambi, Luigi
Radaelli, Marta
Costa, Gloria D.
Lanzillo, Roberta
Lus, Giacomo
Bianchi, Valentina
Traccis, Sebastiano
Capone, Fioravante
Grimaldi, Luigi M. E.
Salemi, Giuseppe
Cardillo, Alessandra
Zipoli, Valentina
MULTIPLE SCLEROSIS JOURNAL-EXPERIMENTAL TRANSLATIONAL AND CLINICAL, 2023, 9 (01)
[24] Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis
Tsantes, E.
Curti, E.
Ferraro, D.
Lugaresi, A.
Baldi, E.
Montepietra, S.
Immovilli, P.
Simone, A. M.
Mancinelli, L.
Strumia, S.
Vitetta, F.
Foschi, M.
Ferri, C.
Ferrarini, C.
Sola, P.
Granella, F.
EUROPEAN JOURNAL OF NEUROLOGY, 2021, 28 (01) : 269 - 277
[25] Persistence with dimethyl fumarate in relapsing-remitting multiple sclerosis: a population-based cohort study
Irene Eriksson
Thomas Cars
Fredrik Piehl
Rickard E. Malmström
Björn Wettermark
Mia von Euler
European Journal of Clinical Pharmacology, 2018, 74 : 219 - 226
[26] The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary
Fricska-Nagy, Zsanett
Fuvesi, Judit
Rozsa, Csilla
Komoly, Samuel
Jakab, Gabor
Csepany, Tunde
Jobbagy, Zita
Lencses, Gyula
Vecsei, Laszlo
Bencsik, Krisztina
MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2016, 7 : 26 - 32
[27] Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews
Mark Gudesblatt
Cortnee Roman
Barry A. Singer
Hollie Schmidt
Jessica Thomas
Sai L. Shankar
Jennifer Lyons
Shivani Kapadia
Advances in Therapy, 2022, 39 : 3199 - 3213
[28] Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews
Gudesblatt, Mark
Roman, Cortnee
Singer, Barry A.
Schmidt, Hollie
Thomas, Jessica
Shankar, Sai L.
Lyons, Jennifer
Kapadia, Shivani
ADVANCES IN THERAPY, 2022, 39 (07) : 3199 - 3213
[29] Quality of life in relapsing-remitting multiple sclerosis patients receiving CinnoVex compared with Avonex
Hatam, Nahid
Bastani, Peivand
Shahtaheri, Rahil Sadat
JOURNAL OF RESEARCH IN PHARMACY PRACTICE, 2016, 5 (03) : 181 - 185
[30] Oral health-related quality of life is more strongly correlated with mental health than with oral health in relapsing-remitting multiple sclerosis
Nangle, Matthew R.
Manchery, Nithin
Swayne, Andrew
Boocock, Helen
Blum, Stefan
Henry, Julie D.
JOURNAL OF ORAL REHABILITATION, 2023, 50 (01) : 62 - 68

← 1 2 3 4 5 →